Vanda D, Zajdel P, Soural M. Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases. Eur J Med Chem. 2019;181:111569.
Devi N, Singh D K, Rawal R, Bariwal J, Singh V. Medicinal attributes of imidazo[1,2-a]pyridine derivatives: an update. Curr Top Medicinal Chem. 2016;16:2963–94.
Mohana Roopan S, Patil SM, Palaniraja J. Recent synthetic scenario on imidazo[1,2-a]pyridines chemical intermediate. Res Chem Intermed. 2016;42:2749–90.
Tashrifi Z, Mohammadi-Khanaposhtani M, Larijani B, Mahdavi M. C3-Functionalization of Imidazo[1,2-a]pyridines. Eur J Org Chem. 2020;2020:269–84.
Ravi C, Adimurthy S. Synthesis of Imidazo[1,2-a]pyridines: C-H Functionalization in the Direction of C-S Bond Formation. Chem Rec. 2017;17:1019–38.
Article CAS PubMed Google Scholar
Hamdouchi C, de Blas J, del Prado M, Gruber J, Heinz BA, Vance L. 2-amino-3-substituted-6-[(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl]imidazo-[1,2-a]pyridines as a novel class of inhibitors of human rhinovirus: Stereospecific synthesis and antiviral activity. J Med Chem. 1999;42:50–9.
Lhassani M, Chavignon O, Chezal J-M, Teulade J-C, Chapat J-P, Snoeck R, et al. Synthesis and antiviral activity of imidazo[1,2-a]pyridines. Eur J Medicinal Chem. 1999;34:271–4.
Véron JB, Allouchi H, Enguehard-Gueiffier C, Snoeck R, Andrei G, de Clercq E, et al. Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): Part II. Bioorg Medicinal Chem. 2008;16:9536–45.
Rival Y, Grassy G, Michel G. Synthesis and antibacterial activity of some imidazo(1,2-a)pyrimidine derivatives. Chem Pharm Bull. 1992;40:1170–6.
Al-Tel TH, Al-Qawasmeh RA. Post Groebke-Blackburn multicomponent protocol: Synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents. Eur J Medicinal Chem. 2010;45:5848–55.
Biftu T, Feng D, Fisher M, Liang GB, Qian X, Scribner A, et al. Synthesis and SAR studies of very potent imidazopyridine antiprotozoal agents. Bioorg Medicinal Chem Lett. 2006;16:2479–83.
Hieke M, Rödl CB, Wisniewska JM, la Buscató E, Stark H, Schubert-Zsilavecz M, et al. SAR-study on a new class of imidazo[1,2-a]pyridine-based inhibitors of 5-lipoxygenase. Bioorg Medicinal Chem Lett. 2012;22:1969–75.
Linz S, Müller J, Hübner H, Gmeiner P, Troschütz R. Design, synthesis and dopamine D4 receptor binding activities of new N-heteroaromatic 5/6-ring Mannich bases. Bioorg Medicinal Chem. 2009;17:4448–58.
Bagdi AK, Santra S, Monir K, Hajra A. Synthesis of imidazo[1,2-a]pyridines: A decade update. Chem Commun. 2015;51:1555–75.
Dhas A, Deshmukh S, Pansare D, Pawar R, Kakade G. Synthesis of Imidazo [1, 2-a] Pyridine Derivatives Using Copper Silicate as an Efficient and Reusable Catalyst. Lett Appl NanoBioScience. 2021;10:2565–70.
Ghosh P, Ganguly B, Kar B, Dwivedi S, Das S. Green procedure for highly efficient, rapid synthesis of imidazo[1,2-a]pyridine and its late stage functionalization. Synth Commun. 2018;48:1076–84.
Sayeed IB, Vishnuvardhan MVPS, Nagarajan A, Kantevari S, Kamal A. Imidazopyridine linked triazoles as tubulin inhibitors, effectively triggering apoptosis in lung cancer cell line. Bioorg Chem. 2018;80:714–20.
Article CAS PubMed Google Scholar
Wu Y, Li L, Wen K, Deng J, Chen J, Shi J. et al. Copper-catalyzed C-3Functionalization of imidazo[1,2- a]pyridines with 3-indoleacetic acids. J Organic Chem. 2021;86:12394–402.
Sayeed I, bin, Lakshma Nayak V, Shareef MA, Chouhan NK, Kamal A. Design, synthesis and biological evaluation of imidazopyridine-propenone conjugates as potent tubulin inhibitors. Medchemcomm 2017;8:1000–6.
Article CAS PubMed PubMed Central Google Scholar
Dahan-Farkas N, Langley C, Rousseau AL, Yadav DB, Davids H, de Koning CB. 6-substituted imidazo[1,2-a]pyridines: Synthesis and biological activity against colon cancer cell lines HT-29 and Caco-2. Eur J Medicinal Chem. 2011;46:4573–83.
Chitrakar R, Rawat D, Sistla R, Vadithe LN, Subbarayappa A. Design, synthesis and anticancer activity of sulfenylated imidazo-fused heterocycles. Bioorganic Med Chem Lett. 2021;49:128307.
Gunaganti N, Kharbanda A, Lakkaniga NR, Zhang L, Cooper R, Yu Li H, et al. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chem Commun. 2018;54:12954–7.
Kamal A, Reddy VS, Karnewar S, Chourasiya SS, Shaik AB, Kumar GB, et al. Synthesis and biological evaluation of imidazopyridine-oxindole conjugates as microtubule-targeting agents. ChemMedChem 2013;8:2015–25.
Article CAS PubMed Google Scholar
Martínez-Urbina MA, Zentella A, Vilchis-Reyes MA, Guzmán Á, Vargas O, Ramírez Apan MT, et al. 6-Substituted 2-(N-trifluoroacetylamino)imidazopyridines induce cell cycle arrest and apoptosis in SK-LU-1 human cancer cell line. Eur J Medicinal Chem. 2010;45:1211–9.
Kim O, Jeong Y, Lee H, Hong SS, Hong S. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis. J Medicinal Chem. 2011;54:2455–66.
Kamal A, Reddy JS, Ramaiah MJ, Dastagiri D, Bharathi EV, Prem Sagar MV, et al. Design, synthesis and biological evaluation of imidazopyridine/pyrimidine- chalcone derivatives as potential anticancer agents. Medchemcomm 2010;1:355–60.
Almeida GM, Rafique J, Saba S, Siminski T, Mota NSRS, Filho DW, et al. Novel selenylated imidazo[1,2-a]pyridines for breast cancer chemotherapy: Inhibition of cell proliferation by Akt-mediated regulation, DNA cleavage and apoptosis. Biochemical Biophysical Res Commun. 2018;503:1291–7.
Lacerda RB, Sales NM, da Silva LL, Tesch R, Miranda ALP, Barreiro EJ, et al. Novel potent imidazo[1,2-a]pyridine-N-glycinyl-hydrazone inhibitors of TNF-α production: in vitro and in vivo studies. PLoS ONE. 2014;9(3):e91660.
Article PubMed PubMed Central Google Scholar
Xi JB, Fang YF, Frett B, Zhu ML, Zhu T, Kong YN, et al. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Medicinal Chem. 2017;126:1083–106.
Aliwaini S, Awadallah AM, Morjan RY, Ghunaim M, Alqaddi H, Abuhamad AY, et al. Novel imidazo[1,2-a]pyridine inhibits AKT/mTOR pathway and induces cell cycle arrest and apoptosis in melanoma and cervical cancer cells. Oncol Lett. 2019;18:830–7.
CAS PubMed PubMed Central Google Scholar
Garamvölgyi R, Dobos J, Sipos A, Boros S, Illyés E, Baska F, et al. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells. Eur J Medicinal Chem. 2016;108:623–43.
Altaher AMH, Adris MA, Aliwaini SH. Imidazo[1,2-a]pyridinebasedcompounds:thehopefulanti-cancer therapy. systematic review. Pharmacy 2021;12:79–85.
Jubeen F, Iqbal SZ, Shafiq N, Khan M, Parveen S, Iqbal M, et al. Eco-friendly synthesis of pyrimidines and its derivatives: A review on broad spectrum bioactive moiety with huge therapeutic profile. Synth Commun. 2018;48:601–25.
Naik TA, Chikhalia KH. Studies on synthesis of pyrimidine derivatives and their pharmacological evaluation. 2007;4(1):60–6.
Malik A, Rasool N, Kanwal I, Hashmi MA, Zahoor AF, Ahmad G, et al. Suzuki–miyaura reactions of (4-bromophenyl)-4,6-dichloropyrimidine through commercially available palladium catalyst: Synthesis, optimization and their structural aspects identification through computational studies. Processes. 2020;8:1–12.
Mahapatra A, Prasad T, Sharma T. Pyrimidine: a review on anticancer activity with key emphasis on SAR. Fut J Pharmaceutical Sci. 2021;7:123.
Tylińska B, Wiatrak B, Czyżnikowska Ż, Cieśla-Niechwiadowicz A, Gębarowska E, Janicka-Kłos A. Novel pyrimidine derivatives as potential anticancer agents: Synthesis, biological evaluation and molecular docking study. Int J Mol Sci. 2021;22(8):3825.
Branković J, Milivojević N, Milovanović V, Simijonović D, Petrović ZD, Marković Z, et al. Evaluation of antioxidant and cytotoxic properties of phenolic N-acylhydrazones: structure–activity relationship. R Soc Open Sci. 2022;9:211853.
Thota S, Rodrigues DA, Pinheiro P, de SM, Lima LM, Fraga CAM, et al. N-Acylhydrazones as drugs. Bioorg Med Chem Lett. 2018;28:2797–806.
Article CAS PubMed Google Scholar
Cardoso LNF, Nogueira TCM, Rodrigues FAR, Oliveira ACA, Luciano MCS, Pessoa C, et al. N-acylhydrazones containing thiophene nucleus: a new anticancer class. Medicinal Chem Res. 2017;26:1605–8.
Do Amaral DN, Cavalcanti BC, Bezerra DP, Ferreira PMP, de Castro RP, Sabino JR, et al. Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues. PLoS ONE. 2014;9(3):e85380.
Samala G, Nallangi R, Devi PB, Saxena S, Yadav R, Sridevi JP, et al. Identification and development of 2-methylimidazo[1,2-a]pyridine-3- carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors. Bioorg Medicinal Chem. 2014;22:4223–32.
Hernández P, Cabrera M, Lavaggi ML, Celano L, Tiscornia I, Rodrigues Da Costa T, et al. Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorg Medicinal Chem. 2012;20:2158–71.
Ribeiro IG, Christine da Silva KM, Parrinil SC, Luisa de Miranda AP, Fraga CA, Barreiro EJ. Synthesis and antinociceptive properties of new structurally planned imidazo[1,2-a]pyridine 3-acylarylhydrazone derivatives. 1998;33(3):225–35.
Musa MA, Cooperwood JS, Khan MOF, Rahman T. In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic Drugs. Arch Pharm (Weinh). 2011;344:102–10.
Theodossiou TA, Ali M, Grigalavicius M, Grallert B, Dillard P, Schink KO, et al. Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy. npj Breast Cancer. 2019;5:13.
Spiegel S, Nohara K, Wang F. Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines. 1998;48(2):149–57.
Shi Y, Ye P, Long X. Differential expression profiles of the transcriptome in breast cancer cell lines revealed by next generation sequencing. Cell Physiol Biochem. 2017;44:804–16.
留言 (0)